Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1924)	10/29/2003 12:01:45 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 3044

Yeah, exactly. Drug development is a long, expensive proposition involving both expertise and luck, with biological luck being one heck of a hurdle. Targets have value. With the glut, however, there's little capacity to assign value to any given unknown. MLNM and Bayer have discovered some shots on goal, but we don't know the venue for the match. Ashley.... yes, you're correct.... it's the same old "Incyte shot on goal" argument. But it's one-level-refined, so we've got about five years to determine if I'm blowing hot air. By then, everyone will have forgotten a bad call. I hope. A little perspective..... Bayer was one of the earliest of biotech participants. Due to completely inept management, they cut back after early, modest success. Of major pharmas, they were THE bunglers with respect to early commitments...... when they did stick their toes in, they bought garbage. Bad timing, bad guidance. And then biotech was producing big progress in the clinic and on bottom lines. Panic! "What the hell do we do now?", rang out in Leverkeusen. And they finally did something smart. They signed the MLNM and CRGN deals, which would force their internal engines to come up to speed. That takes time. There is, undoubtedly, enormous focus at Bayer to weed through the prospects.